The p53-mdm-2 autoregulatory feedback loop.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Genes & Development

• Publication date

  1993-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/GAD.7.7A.1126PMID 8319905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth

  1993cited by this paper
• Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.

  1993cited by this paper
• A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

  1992cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• Wild-type p53 activates transcription in vitro

  1992cited by this paper
• Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

  1992cited by this paper
• Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.

  1992cited by this paper
• A transcriptionally active DNA-binding site for human p53 protein complexes

  1992influential reference
• The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein.

  1992influential reference
• Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53‐mediated growth arrest.

  1992cited by this paper
• Wild-type p53 binds to the TATA-binding protein and represses transcription.

  1992cited by this paper
• Definition of a consensus binding site for p53

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

  1991cited by this paper
• THE P53 TUMOR SUPPRESSOR GENE

  1991cited by this paper
• p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts.

  1991cited by this paper
• Transcriptional repression by YY1, a human GLI-Krüppel-related protein, and relief of repression by adenovirus E1A protein.

  1991cited by this paper
• Identification of p53 as a sequence-specific DNA-binding protein

  1991influential reference
• The p53 tumour suppressor gene

  1991cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.

  1991influential reference
• Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

  1990cited by this paper
• Association of human papillomavirus types 16 and 18 E6 proteins with p53.

  1990cited by this paper
• Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

  1990cited by this paper
• Presence of a potent transcription activating sequence in the p53 protein.

  1990cited by this paper
• Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

  1990influential reference
• Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen.

  1990cited by this paper
• The p53 proto-oncogene can act as a suppressor of transformation.

  1989cited by this paper
• Expression and complex formation of simian virus 40 large T antigen and mouse p53 in insect cells

  1988cited by this paper
• Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines

  1987cited by this paper
• Monoclonal antibody analysis of p53 expression in normal and transformed cells

  1986cited by this paper
• Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

  1982cited by this paper
• Binding of a simian virus 40 T antigen-related protein to DNA.

  1981cited by this paper
• Complex of simian virus 40 large-T antigen and host 53,000-molecular-weight protein in monkey cells

  1981cited by this paper
• T antigen is bound to a host protein in SY40-transformed cells

  1979cited by this paper
• Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.

  1979cited by this paper
• A new technique for the assay of infectivity of human adenovirus 5 DNA.

  1973cited by this paper

• Switching off CK2-mediated activation of survivin offers new therapeutic opportunities in neuroblastoma

  2026cites this paper
• Genetic resonance in the p53 signaling network.

  2026cites this paper
• The evolution of Nutlins as p53-MDM2 inhibitors

  2025cites this paper
• A Dual-Specificity d-Peptide Antagonist of MDM2 and MDMX for Antitumor Immunotherapy.

  2025cites this paper
• Machine Learning‐Guided Discovery of Natural MDM2 Inhibitors: A Multistage In Silico Pipeline from Screening to ADMET Profiling

  2025cites this paper
• Acetylation: a new target for protein degradation in cancer.

  2025cites this paper
• A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT.

  2025cites this paper
• The role of HECT-type E3 ubiquitin ligases in DNA damage response and repair

  2025cites this paper
• Magnet-Responsive Nanomaterials Trigger Ferroptosis and Cellular Senescence Modulation via p53/SLC7A11 Axis for Tumor Therapy.

  2025cites this paper
• Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

  2025cites this paper
• Development of MDM2‐Targeting PROTAC for Advancing Bone Regeneration

  2025cites this paper
• Anticancer effects and mechanisms of Pulsatilla chinensis, Bupleurum chinense and Polyporus umbellatus on human lung carcinoma and hepatoma cells

  2025cites this paper
• The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy

  2025cites this paper
• Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells

  2025cites this paper
• Correlation of p53 oligomeric status and its subcellular localization in the presence of the AML-associated NPM mutant

  2025cites this paper
• Loss of NUMB promotes hepatomegaly and hepatocellular carcinoma through the AKT/glycogen/hippo signaling

  2025cites this paper
• Endocytic control of cell-autonomous and non-cell-autonomous functions of p53

  2025cites this paper
• Discovery of Furopyrimidine‐Pyrazole Hybrid Compounds Targeting p53‐MDM2 Interaction as Anticancer Agents

  2025cites this paper
• Exploring 2,5-diphenyl furan derivative as promising inhibitor of p53-MDM2 interaction for cancer therapy

  2025cites this paper
• In-frame germline TP53 variant impairs p53 oligomerization and predisposes to cancer

  2025cites this paper
• TTLL4 mediates the PI3K/AKT/MDM2 pathway to promote hepatocellular carcinoma progression and predict patient prognosis

  2025cites this paper
• In-silico approaches to unravel the efficacy of naturally occurring C–C and C–O–C type biflavonoids towards the inhibition of MDM2–p53 interactions

  2025cites this paper
• Effect of Eupatorium adenophorum Extract on p53 Protein in Cancer Treatment

  2025cites this paper
• GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.

  2025cites this paper
• Divergent PTEN–p53 interaction upon DNA damage in a human thyroid organoid model with germline PTEN mutations

  2025cites this paper
• Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment

  2024cites this paper
• The distribution of fitness effects during adaptive walks using a simple genetic network

  2024influential citation
• Ubiquitin-Mediated Effects on Oncogenesis during EBV and KSHV Infection

  2024cites this paper
• Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia

  2024cites this paper
• FBXO46 negatively regulates p53 activity by stabilizing Mdm2

  2024cites this paper
• The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress

  2024cites this paper
• Activation of the Snail transcription factor induces Mdm2 gene expression

  2024cites this paper
• Entrainment and multi-stability of the p53 oscillator in human cells.

  2024cites this paper
• PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA

  2024cites this paper
• Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

  2024cites this paper
• KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors

  2024cites this paper
• tp53 R217H and R242H Mutant Zebrafish Exhibit Dysfunctional p53 Hallmarks and Recapitulate Li-Fraumeni Syndrome Phenotypes

  2024cites this paper
• Interaction Analysis by Fragment Molecular Orbital Method for Drug Discovery Research.

  2024cites this paper
• Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia

  2024cites this paper
• MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53

  2024cites this paper
• An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy.

  2024cites this paper
• Effects of vitamin D signaling in cardiovascular disease: centrality of macrophage polarization

  2024cites this paper
• Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.

  2024cites this paper
• Exercise improves muscle mitochondrial dysfunction-associated lipid profile under circadian rhythm disturbance

  2024cites this paper
• MDM2 inhibitors in cancer immunotherapy: Current status and perspective

  2024cites this paper
• P53 upregulation by USP7-engaging molecular glues.

  2024cites this paper
• The human adenovirus PI3K-Akt activator E4orf1 is targeted by the tumor suppressor p53

  2024cites this paper
• Determinants of p53 DNA binding, gene regulation, and cell fate decisions

  2024cites this paper
• Role of the ubiquitin–proteasome system on macrophages in the tumor microenvironment

  2024cites this paper
• MDMX in Cancer: A Partner of p53 and a p53-Independent Effector

  2024cites this paper
• Primary dedifferentiated liposarcoma of the gallbladder: a case report and literature review.

  2024cites this paper
• A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT.

  2024cites this paper
• Induction of the Mdm2 gene and protein by kinase signaling pathways is repressed by the pVHL tumor suppressor

  2024cites this paper
• An update patent review of MDM2–p53 interaction inhibitors (2019–2023)

  2024cites this paper
• Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus.

  2024cites this paper
• Anticancer therapeutic strategies for targeting mutant p53-Y220C

  2023cites this paper
• MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy

  2023cites this paper
• Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction

  2023cites this paper
• Targeting MDM2 for the development of a new cancer therapy: progress and challenges

  2023cites this paper
• MLF2 Negatively Regulates P53 and Promotes Colorectal Carcinogenesis

  2023cites this paper
• Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity

  2023cites this paper
• Silencing of FAM111B inhibited proliferation, migration and invasion of hepatoma cells through activating p53 pathway.

  2023cites this paper
• Roles of NOLC1 in cancers and viral infection

  2023cites this paper
• Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy

  2023cites this paper
• Modeling wild type and mutant p53 in telomerase-immortalized human cells

  2023cites this paper
• Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia

  2023cites this paper
• Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma

  2023cites this paper
• The mechanism accounting for DNA damage strength modulation of p53 dynamical properties

  2023cites this paper
• Metal-Based Anticancer Complexes and p53: How Much Do We Know?

  2023cites this paper
• The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis.

  2023cites this paper
• Fine tuning of the transcription juggernaut: A sweet and sour saga of acetylation and ubiquitination.

  2023cites this paper
• The roles of TPL in hematological malignancies

  2023cites this paper
• MiRNA Differences Related to Treatment-Resistant Schizophrenia

  2023cites this paper
• In vivo RNA-seq and ChIP-seq analyses show an obligatory role for the C terminus of p53 in conferring tissue-specific radiation sensitivity

  2023cites this paper
• Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold.

  2023cites this paper
• Utility of atherosclerosis-associated serum antibodies against colony-stimulating factor 2 in predicting the onset of acute ischemic stroke and prognosis of colorectal cancer

  2023cites this paper
• Acquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension

  2023cites this paper
• The SWIB/MDM2 motif of UBE4B activates the p53 pathway

  2023cites this paper
• Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program

  2023cites this paper
• c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53

  2023cites this paper
• Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors

  2023cites this paper
• Dynamic behavior of P53-Mdm2-Wip1 gene regulatory network under the influence of time delay and noise.

  2023cites this paper
• Soluble peptidoglycan fragments produced by Limosilactobacillus fermentum with antiproliferative activity are suitable for potential therapeutic development: A preliminary report

  2023cites this paper
• The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells.

  2023cites this paper
• Senescent cells limit p53 activity via multiple mechanisms to remain viable

  2022cites this paper
• Ribosomopathies and cancer: pharmacological implications

  2022cites this paper
• Electronic Polarization at the Interface between the p53 Transactivation Domain and Two Binding Partners.

  2022cites this paper
• Exploiting Extracellular Vesicles Strategies to Modulate Cell Death and Inflammation in COVID-19

  2022cites this paper
• Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma

  2022cites this paper
• p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways

  2022cites this paper
• Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress

  2022cites this paper
• Deficiency of ribosomal proteins reshapes the transcriptional and translational landscape in human cells

  2022cites this paper
• Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187

  2022cites this paper
• RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations

  2022cites this paper
• Strategies for designing proteolysis targeting chimaeras (PROTACs)

  2022cites this paper
• p53 regulation by ubiquitin and ubiquitin-like modifications

  2022cites this paper
• Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response–dependent destabilization of tumor protein P53

  2022cites this paper
• The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.

  2022cites this paper
• Multifaceted functions of RPS27a: An unconventional ribosomal protein

  2022cites this paper
• Therapeutic Strategies to Activate p53

  2022influential citation